Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients

Marc Miravitlles, Esther Garcia Gil, Ferran Chuecos, Rosa Lamarca
European Respiratory Journal 2015 46: OA1968; DOI: 10.1183/13993003.congress-2015.OA1968
Marc Miravitlles
1Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Garcia Gil
2Global Medicines Development, AstraZeneca PLC, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferran Chuecos
2Global Medicines Development, AstraZeneca PLC, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Lamarca
3R&D Centre, Almirall S.A., Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: Morning and nighttime symptoms of COPD impair patient quality of life.

Methods: Data were pooled from two 24-week, randomised, placebo-controlled, Phase III studies of twice-daily aclidinium/formoterol fixed-dose combination (FDC) in moderate to severe COPD (NCT01462942 & NCT01437397). Morning and nighttime symptom prevalence was assessed, and patient characteristics and efficacy of FDC 400/12 µg were compared for symptomatic (cough, wheezing, dyspnoea and phlegm, both morning and night at baseline) vs asymptomatic patients (no symptoms at baseline either morning or night).

Results: Data were analysed for 3339 patients. Symptoms were common in the morning (cough 81.5%; dyspnoea 77.6%; wheeze 63.4%; phlegm 48.6%) and at night (cough 72.7%; dyspnoea 67.2%; wheeze 59.3%; phlegm 44.0%). Compared with asymptomatic patients, symptomatic patients were more likely to be male, smokers, with more severe COPD and lower predicted FEV1, and to have had exacerbations in the last year. FDC 400/12 µg improved FEV1 and TDI (dyspnoea related to daily activities) in both symptomatic and asymptomatic patients, and E-RS (symptoms) in symptomatic patients (Table).

Conclusion: Morning and nighttime COPD symptoms are common in moderate to severe COPD. Aclidinium/formoterol FDC 400/12 µg significantly improved symptoms vs placebo, and improved dyspnoea and lung function in symptomatic and asymptomatic patients.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

  • COPD - management
  • Bronchodilators
  • Cough
  • Copyright ©ERS 2015
Previous
Back to top
Vol 46 Issue suppl 59 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients
Marc Miravitlles, Esther Garcia Gil, Ferran Chuecos, Rosa Lamarca
European Respiratory Journal Sep 2015, 46 (suppl 59) OA1968; DOI: 10.1183/13993003.congress-2015.OA1968

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients
Marc Miravitlles, Esther Garcia Gil, Ferran Chuecos, Rosa Lamarca
European Respiratory Journal Sep 2015, 46 (suppl 59) OA1968; DOI: 10.1183/13993003.congress-2015.OA1968
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Blood eosinophils and outcomes in COPD
  • Long-term survivalaccording to Czech clinical phenotypes of COPD- Czech multicentre research database of severe COPD
  • Assessment of lung volumes and capacities in bronchodilator reversibility changes of hyperinflation of COPD
Show more 1.12 Clinical Problems - COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society